Jupiter Asset Management Ltd. trimmed its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 68.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,275 shares of the biotechnology company’s stock after selling 67,415 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Aurinia Pharmaceuticals were worth $243,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the stock. Sunbelt Securities Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the 1st quarter valued at about $31,000. Geneos Wealth Management Inc. grew its holdings in Aurinia Pharmaceuticals by 54.2% during the first quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 1,142 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Aurinia Pharmaceuticals by 95.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,798 shares during the period. Focused Wealth Management Inc acquired a new stake in shares of Aurinia Pharmaceuticals in the second quarter worth $48,000. Finally, Lazard Asset Management LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 164.7% during the 1st quarter. Lazard Asset Management LLC now owns 5,300 shares of the biotechnology company’s stock worth $65,000 after buying an additional 3,298 shares during the period. 39.64% of the stock is currently owned by institutional investors.
Aurinia Pharmaceuticals Stock Performance
NASDAQ:AUPH opened at $8.29 on Monday. The firm has a market capitalization of $1.19 billion, a PE ratio of -15.64 and a beta of 1.46. Aurinia Pharmaceuticals Inc. has a 1 year low of $6.94 and a 1 year high of $12.43. The company has a current ratio of 5.77, a quick ratio of 5.33 and a debt-to-equity ratio of 0.18. The firm’s fifty day simple moving average is $8.47 and its 200 day simple moving average is $8.60.
Aurinia Pharmaceuticals Profile
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
- Five stocks we like better than Aurinia Pharmaceuticals
- Insider Trading – What You Need to Know
- Uber quadruples EPS estimates, but is growth decelerating?
- How to Invest in EV Charging Stations
- 3 stocks set to benefit from record Valentine’s Day spending
- How to Invest in Small Cap Stocks
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.